losartan has been researched along with Epilepsy in 10 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Epilepsy: A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)
| Excerpt | Relevance | Reference |
|---|---|---|
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 7.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 6.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
| " We propose losartan, a drug approved by the US Food and Drug Administration, as an efficient antiepileptogenic therapy for epilepsy associated with vascular injury." | 3.80 | Losartan prevents acquired epilepsy via TGF-β signaling suppression. ( Bar-Klein, G; Cacheaux, LP; Cheng, P; Friedman, A; Heinemann, U; Kamintsky, L; Kaufer, D; Kim, SY; Prager, O; Schoknecht, K; Weissberg, I; Wood, L, 2014) |
| "Valproic acid is a widely used anticonvulsant drug with a broad therapeutic spectrum." | 2.73 | Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. ( Babaoglu, MO; Bilir, E; Bozkurt, A; Gunes, A; Yasar, U; Zengil, H, 2007) |
| " Furthermore, most preclinical antiepileptogenic studies lack information needed for translation, such as dose-blood level relationship, brain target engagement, and dose-response, and many use treatment parameters that cannot be applied clinically, for example, treatment initiation before or at the time of injury and dosing higher than tolerated human equivalent dosing." | 2.66 | Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy? ( Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Slomski, A | 2 |
| Klein, P | 1 |
| Friedman, A | 2 |
| Hameed, MQ | 1 |
| Kaminski, RM | 1 |
| Bar-Klein, G | 2 |
| Klitgaard, H | 1 |
| Koepp, M | 1 |
| Jozwiak, S | 1 |
| Prince, DA | 1 |
| Rotenberg, A | 1 |
| Twyman, R | 1 |
| Vezzani, A | 1 |
| Wong, M | 1 |
| Löscher, W | 1 |
| Atanasova, D | 1 |
| Tchekalarova, J | 1 |
| Ivanova, N | 1 |
| Nenchovska, Z | 1 |
| Pavlova, E | 1 |
| Atanassova, N | 1 |
| Lazarov, N | 1 |
| Nozaki, T | 1 |
| Ura, H | 1 |
| Takumi, I | 1 |
| Kobayashi, S | 1 |
| Maru, E | 1 |
| Morita, A | 1 |
| Palestro, PH | 1 |
| Enrique, N | 1 |
| Goicoechea, S | 1 |
| Villalba, ML | 1 |
| Sabatier, LL | 1 |
| Martin, P | 1 |
| Milesi, V | 1 |
| Bruno Blanch, LE | 1 |
| Gavernet, L | 1 |
| Hong, S | 1 |
| JianCheng, H | 1 |
| JiaWen, W | 1 |
| ShuQin, Z | 1 |
| GuiLian, Z | 1 |
| HaiQin, W | 1 |
| Ru, Z | 1 |
| Zhen, G | 1 |
| HongWei, R | 1 |
| Cacheaux, LP | 1 |
| Kamintsky, L | 1 |
| Prager, O | 1 |
| Weissberg, I | 1 |
| Schoknecht, K | 1 |
| Cheng, P | 1 |
| Kim, SY | 1 |
| Wood, L | 1 |
| Heinemann, U | 1 |
| Kaufer, D | 1 |
| Pereira, MG | 1 |
| Becari, C | 1 |
| Oliveira, JA | 1 |
| Salgado, MC | 1 |
| Garcia-Cairasco, N | 1 |
| Costa-Neto, CM | 1 |
| Ueno, Y | 1 |
| Takagi, A | 1 |
| Kawana, M | 1 |
| Kasanuki, H | 1 |
| Gunes, A | 1 |
| Bilir, E | 1 |
| Zengil, H | 1 |
| Babaoglu, MO | 1 |
| Bozkurt, A | 1 |
| Yasar, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients[NCT05637216] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-08-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for losartan and Epilepsy
| Article | Year |
|---|---|
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Cef | 2020 |
1 trial available for losartan and Epilepsy
| Article | Year |
|---|---|
Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients.
Topics: Adolescent; Adult; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liq | 2007 |
8 other studies available for losartan and Epilepsy
| Article | Year |
|---|---|
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan Decreases Incidence of Epilepsy in Arterial Hypertension.
Topics: Epilepsy; Humans; Hypertension; Incidence; Losartan | 2022 |
Losartan suppresses the kainate-induced changes of angiotensin AT
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Blood Pressure; Como | 2018 |
The angiotensin II type I receptor antagonist losartan retards amygdala kindling-induced epileptogenesis.
Topics: Amygdala; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Brain Injuries; Cerebral | 2018 |
Searching for New Leads To Treat Epilepsy: Target-Based Virtual Screening for the Discovery of Anticonvulsant Agents.
Topics: Animals; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Ciprofloxacin; Da | 2018 |
Losartan inhibits development of spontaneous recurrent seizures by preventing astrocyte activation and attenuating blood-brain barrier permeability following pilocarpine-induced status epilepticus.
Topics: Animals; Astrocytes; Blood-Brain Barrier; Brain; Disease Models, Animal; Epilepsy; Losartan; Male; N | 2019 |
Losartan prevents acquired epilepsy via TGF-β signaling suppression.
Topics: Animals; Animals, Newborn; Anticonvulsants; Astrocytes; Benzamides; Blood-Brain Barrier; Cells, Cult | 2014 |
Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticonv | 2010 |
Pulmonary hypertension during epileptic seizure with evidence of increased angiotensin II in pulmonary artery.
Topics: Aged; Angiotensin II; Anticonvulsants; Catheterization, Swan-Ganz; Drug Therapy, Combination; Epilep | 2005 |